Recorded fact · drug.label_indication
drug.label_indication for teriflunomide|multiple-sclerosis
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 167cf3f2 resolves to.
The record
| Fact id | 167cf3f254d3dbfae2c675d0 |
|---|---|
| Entity | drug: teriflunomide|multiple-sclerosis |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20220824 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: c6888eb65af751de9341b3bc23a8527c3e35dfe7379846a8ccd649a546e4e06a.
The value
{
"ingredient": "Teriflunomide",
"conditionId": "multiple-sclerosis",
"conditionName": "Multiple Sclerosis",
"matchedAlias": "multiple sclerosis",
"context": "indication",
"brand": "Teriflunomide",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "1824aae5-58af-43da-8231-435c8f118bc0",
"labelEffectiveTime": "20220824",
"labelsRead": 14,
"labelsNaming": 14,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 0b3c6eb9a06a33e62f1d2dc82dd31bba77902e4c51a4c9320e0fe542d82f483a.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.